New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
16:30 EDTSTRI, MAPP, HLF, MCP, COH, GOOG, FSLR, AGN, CREE, IBM On The Fly: Closing Wrap
Stocks on Wall Street were higher following better than expected earnings from tech giants IBM (IBM) and Google (GOOG). Near midday, the House voted to extend the debt limit until May 19, as expected, and the markets did not react to the news. Eyes on the Street are focused on this evening's report from Nasdaq's largest component, Apple (AAPL)... ECONOMIC EVENTS: In the U.S., the light economic calendar included the Home Price Index, which showed prices rose 0.6% in November, versus expectations for an increase of 0.7%. Also of note, the International Monetary Fund lowered its outlook for 2013 global output growth to 3.5% from 3.6%... COMPANY NEWS: IBM shares gained $8.64, or 4.41%, to $204.72 after its earnings report and guidance exceeded expectations. Google similarly reported earnings that beat consensus. A number of firms increased their price targets on shares, including Jefferies taking their target up to $875. Google advanced $38.63, or 5.5%, to $741.50 following its earnings report... Herbalife (HLF) was again in the news as Greenlight Capital's quarterly letter to investors made the rounds this afternoon. There was some speculation that the letter contained a veiled reference to a short position in Herbalife, however, The Wall Street Journal reported that Greenlight's David Einhorn told investors he does not currently have any bet on the stock. However, Einhorn admitted to profiting from a short position in Herbalife held in 2012 that has since been closed. Shares of Herbalife were down $1.13, or 2.56%, to $43.01 on the day... Among notable companies moving after reporting earnings were Cree (CREE), up $7.38, or 22.05%, to $40.85 after beating expectations, and Coach (COH), down $9.93, or 16.36%, to $50.75 after its earnings fell short of expectations and its Q4 SSS fell 2%... MAJOR MOVERS: Among notable gainers was MAP Pharmaceuticals (MAPP), which rose $9.13, or 58.6%, to $24.71 after it was announced last night that the company had agreed to be acquired by Allergan (AGN) for $25 per share. Allergan shares fell $1.10, or 1.04%, to $104.65 following the announcement. Among notable losers was Molycorp (MCP), which fell 95c, or 10.76%, to $7.88 after disclosing that the company sees Q4 and 1H13 production below expectations and shares were downgraded at Dahlman Rose. Also lower were shares of STR Holdings (STRI), down 79c, or 25.48%, to $2.31 after announcing last night that it expects to lose First Solar (FSLR) as a customer and shares were downgraded to Hold at Craig-Hallum... INDICES: The Dow was up 66.96, or 0.49%, to 13,779.17; the Nasdaq was up 10.49, or 0.33%, to 3,153.67; and the S&P 500 was up 2.22, or 0.15%, to 1,494.78.
News For IBM;GOOG;HLF;CREE;COH;MAPP;AGN;MCP;STRI;FSLR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
November 17, 2014
09:34 EDTAGNCombined Actavis-Allergan to be led by Actavis CEO Saunders
Actavis (ACT) and Allergan (AGN) said The combined company will be led by Brent Saunders, CEO and President of Actavis, and Paul Bisaro will remain Executive Chairman of the Board. The integration of the two companies will be led by the senior management teams of both companies, with integration planning to begin immediately in order to transition rapidly to a single company. Additionally, two members of the Allergan board of directors will be invited to join the Actavis Board of Directors following the completion of the transaction.
09:32 EDTAGNValeant says cannot justify paying $219 per share for Allergan
Valeant Pharmaceuticals (VRX) commented on the announcement that Allergan (AGN) and Actavis (ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock: "We have seen the announcement that Allergan and Actavis have made, and while we will review any such agreement in determining our course of action, Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan. Our business is performing extremely well as evidenced by our third quarter results, our expected strong fourth quarter, and our robust outlook for 2015, and I am confident in our continued ability to generate exceptional shareholder value. We will remain focused on delivering strong organic results and evaluating acquisition opportunities as we always have: prudently, in a disciplined manner, and in the best interests of our shareholders."
09:29 EDTAGNActavis to host conference call
Conference call to discuss the acquisition of Allergan will be held on November 17 at 10:30 am. Webcast Link
09:24 EDTAGNAllergan up over 5% to $209 after agreeing to be acquired by Actavis
Subscribe for More Information
09:21 EDTAGNActavis, Allergan transaction subject to approval of shareholders of both
Subscribe for More Information
09:20 EDTAGNActavis projects at least $1.8B in annual synergies from Allergan transaction
Subscribe for More Information
09:18 EDTAGNActavis sees free cash flow over $8B in 2016 following Allergan acquisition
Subscribe for More Information
09:16 EDTAGNActavis confirms deal to acquire Allergan for $219 in cash, stock
Subscribe for More Information
09:15 EDTAGNActavis confirms deal to acquire Allergan for $219 in cash and shares
Subscribe for More Information
09:10 EDTAGNActavis buying Allergan for $219 per share, CNBC reports
07:52 EDTIBMDepartment of Energy awards $425M for supercomputing technologies
Subscribe for More Information
06:23 EDTGOOGFacebook working on 'Facebook at Work' website, FT reports
Subscribe for More Information
06:10 EDTGOOGGoogle partners with Telstra to test Project Loon in Australia, SMH reports
Subscribe for More Information
06:07 EDTCREEStocks with implied volatility below IV index mean; CREE V
Stocks with implied volatility below IV index mean; Cree (CREE) 37, Visa (V) 17 according to iVolatility.
06:05 EDTAGNActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
November 16, 2014
14:02 EDTAGNAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
November 14, 2014
17:07 EDTHLF, GOOGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
16:39 EDTIBMBerkshire Hathaway gives quarterly update on stakes
Subscribe for More Information
08:07 EDTHLFHerbalife director linked to Brazilian fraud case, Reuters reports
Subscribe for More Information
06:00 EDTGOOGGoogle to retire Google Wallet for digital goods API on March 2, 2015
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use